49822-54-0

Upstream product

• 49822-53-9 2-[bis-(4-chloro-phenyl)-hydroxy-methyl]-1-(toluene-4-sulfonyl)-1H-imidazole 
• 111456-84-9 1-(1,1-diethoxyethyl)imidazole 
• 90-98-2 4,4'-Dichlorobenzophenone 

Downstream Products

• 123124-62-9 C₁₉H₁₄Cl₂N₄ 
• 49823-09-8 (1-benzyl-1H-imidazol-2-yl)-bis-(4-chloro-phenyl)-methanol 
• 49823-19-0 bis-(4-chloro-phenyl)-(1-methyl-1H-imidazol-2-yl)-methanol 
• 49823-21-4 (1-benzyloxymethyl-1H-imidazol-2-yl)-bis-(4-chloro-phenyl)-methanol 

Relevant academic research and scientific papers

Estrogen Synthetase Inhibitors. 2. Comparison of the in Vitro Aromatase Inhibitory Activity for a Variety of Nitrogen Heterocycles Substituted with Diarylmethane or Diarylmethanol Groups

The preparation and in vitro aromatase inhibitory activity of a wide variety of heterocyclic (4,4'-dichlorodiphenyl)methanes and -methanols are described.The choice of the two diaryl-bearing moieties as a vehicle for the evaluation of the heterocycles was made by the comparison of series of imidazole and pyridine-derived compunds with similar pyrimidine compounds reported previously.A structural model for the most active compounds is also presented.The activity of a related series of compounds which contain two heterocyclic moieties was found to be consistent with the model.Many of the compounds evaluated, including representatives of the pyridine, imidazole, pyrimidine, pyrazole, triazole, thiazole, and isothiazole classes, exhibit EC50 potencies for aromatase inhibition at low nanomolar levels.These compunds are at least as potent as other nonsteroidal aromatase inhibitors reported previously.

Analgesic imidazolemethanols

α,α-Diarylimidazole-2-methanols of the general formula STR1 wherein R1 -R10 are the same or different and each represents a hydrogen or halogen atom or a trifluoromethyl or tertiary butyl group, with at least one of said R1 -R10 being halogen, trifluoromethyl or tertiary butyl; R11 and R12 are the same or different and each represents a hydrogen atom, an alkyl group, a phenyl group or a halogen-or trifluoromethyl-substituted phenyl group; and R13 represents a hydrogen atom or a lower alkyl group, a lower alkoxymethyl group, a phenylalkyl group (optionally substituted in the phenyl moiety by one or more halogen atoms or alkyl or trifluoromethyl groups), an alkenyl group, a phenyl(lower)alkoxymethyl group (optionally substituted in the phenyl moiety by one or more halogen atoms or alkyl or trifluoromethyl groups) or a benzenesulfonyl group (in which the phenyl moiety is optionally substituted by one or more alkyl groups) are described. These compounds and their non-toxic acid addition salts have anorexient activity. Certain of these compounds have analgesic activity comparable to morphine but without its serious side effects. Processes for their manufacture and compositions for their use are described.